GRCE Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 9.3%, SMA50 13.14%, SMA200 27.95%). The stock’s 14-day RSI is 65.97 (firm momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -4.19% below its high and over 135.43% above its low. Average 10-day trading volume of 240.35 thousand shares is below the 3-month average of 676.23 thousand, indicating normal recent market interest.

Grace Therapeutics, Inc. has 13.83 million shares outstanding. The public float is 7.48 million shares, elevated short interest at 0.66% of float. This equals 76.31 thousand shares. The short ratio is 1.17 days. Institutional investors hold 39.65% of the float. Insiders own 30.28%.

Grace Therapeutics, Inc. generated EPS of -$0.36 over the past year. Five-year average earnings growth is 44.08%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $8.00. The high target offers 236.13% upside. The low target suggests 236.13% downside. The mean target is $8.00. This offers 236.13% upside. Grace Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended February 12, 2026, missed forecasts by 55.56%. The prior quarter beat by -64.81%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 13, 2024.

Grace Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.73. This means the shares are trading above this model’s fair value.

Grace Therapeutics, Inc. (NASDAQ:GRCE) closed at $2.38 USD, gaining $0.16 (7.21%) from the previous close of $2.22. The stock is currently mid-range between its 52-week high and low $1.79 and $5.18. With a market capitalization of about $36.83 million, Grace Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.36). Key stats such as the average daily volume over the past year has been around 733.57 thousand shares, volume is running light vs its 52-week average. Headquartered in Princeton, NJ, Grace Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Prashant Kohli, the company employs approximately 4 people and listed since February 07, 2012. Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada.

Grace Therapeutics, Inc. trades at a P/E ratio of -3.95, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.59 suggesting the stock is closer to book value. The P/FCF stands at -3.96, also above market averages.

Our AI price prediction model suggests that Grace Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.68%, with price expected at $2.34 by July 02, 2026, within a range of $2.20 to $2.48 3-Month Outlook: Projected rise of 136.97%, reaching $5.64 by September 16, 2026, with a range of $5.37 to $6.00. 1-Year Outlook: Projected gain of 717.65%, with price at $19.46 by June 18, 2027, within a range of $19.42 to $19.55.

Grace Therapeutics, Inc. (NASDAQ:GRCE) shares are flat 3.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Grace Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.95. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.00, suggesting 320.17% upside. Our AI forecast model points to short-term weakness (-1.68% over two weeks), a medium-term rise (136.97% over three months), and a longer-term gain (717.65% over one year), with expected trading ranges indicating moderate volatility.